Zimmer Biomet Holdings, Inc.

Equities

ZBH

US98956P1021

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX 09:36:44 2024-05-03 am EDT 5-day change 1st Jan Change
119.7 USD +1.03% Intraday chart for Zimmer Biomet Holdings, Inc. -1.08% -2.66%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Citigroup Adjusts Price Target on Zimmer Biomet to $134 From $140 MT
Morgan Stanley Adjusts Price Target on Zimmer Biomet to $130 From $135 MT
Jefferies Adjusts Zimmer Biomet Price Target to $135 From $136 MT
Citigroup Adjusts Zimmer Biomet Price Target to $134 From $140 MT
Morgan Stanley Adjusts Zimmer Biomet Price Target to $130 From $135 MT
Oppenheimer Adjusts Price Target on Zimmer Biomet Holdings to $155 From $150 MT
BTIG Adjusts Price Target on Zimmer Biomet to $139 From $138, Keeps Buy Rating MT
Transcript : Zimmer Biomet Holdings, Inc., Q1 2024 Earnings Call, May 02, 2024
Zimmer Biomet beats Q1 profit estimates on robust demand for knee, hip devices RE
Zimmer Biomet Holdings Q1 Adjusted Earnings, Net Sales Rise; 2024 Outlook Reiterated MT
(ZBH) ZIMMER BIOMET HOLDINGS Expects Fiscal Year 2024 EPS Range $8.00 - $8.15 MT
Earnings Flash (ZBH) ZIMMER BIOMET HOLDINGS Reports Q1 Revenue $1.89B, vs. Street Est of $1.87B MT
Earnings Flash (ZBH) ZIMMER BIOMET HOLDINGS Posts Q1 EPS $1.94, vs. Street Est of $1.87 MT
Zimmer Biomet Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Zimmer Biomet Holdings, Inc. Reiterates Financial Guidance for Current Full-Year 2024 CI
North American Morning Briefing : Stock Futures -2- DJ
Truist Securities Adjusts Zimmer Biomet Price Target to $137 From $135, Hold Rating Kept MT
Zimmer Biomet Partners with Three Pickleball Organizations in US MT
Citigroup Raises Price Target on Zimmer Biomet to $140 From $134, Keeps Neutral Rating MT
3M Board Approves Healthcare Unit Spinoff -- Update DJ
Zimmer Biomet's ROSA Shoulder Replacement Platform Receives FDA Clearance MT
Zimmer Biomet Holdings, Inc. Announces U.S. Food and Drug Administration 510(K) Clearance of the Rosa® Shoulder System for Robotic-Assisted Shoulder Replacement Surgery CI
Zimmer Biomet Maintains Quarterly Dividend at $0.24 a Share, Payable by April 30 to Shareholders of Record March 29 MT
Zimmer Biomet Holdings, Inc. Announces Quarterly Cash Dividend for the First Quarter of 2024, Payable on or About April 30, 2024 CI
Smith & Nephew Q4 Margin in Focus, Outlook Upgrade Likely, RBC Says MT
Chart Zimmer Biomet Holdings, Inc.
More charts
Zimmer Biomet Holdings, Inc. specializes in designing, manufacturing, and selling orthopedic and dental reconstruction implants, spinal implants, and traumatology products. Net sales break down by family of products as follows: - reconstruction implants (57.5%): knees replacement (58.8% of net sales), hips replacement (41.2%); - surgical products and traumatology equipment (22.1%); - dental, spinal and craniomaxillofacial implants (12.8%); - other (7.6%): primarily orthopedic surgery materials and instruments used during post-operative rehabilitation. At the end of 2021, the group had approximately 30 production sites worldwide. Net sales are distributed geographically as follows: Americas (61.3%), Europe/Middle East/Africa (21.3%) and Asia/Pacific (17.4%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
118.5 USD
Average target price
136.6 USD
Spread / Average Target
+15.32%
Consensus
  1. Stock Market
  2. Equities
  3. ZBH Stock
  4. News Zimmer Biomet Holdings, Inc.
  5. Earnings Flash (ZBH) ZIMMER BIOMET HOLDINGS Posts Q2 EPS $1.82